Division of Transplant Surgery, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
Department of Pharmacy Services, Ralph H Johnson VAMC, Charleston, SC, USA.
Transpl Int. 2019 Jan;32(1):84-94. doi: 10.1111/tri.13338. Epub 2018 Sep 16.
An improved understanding of the impact of clinical surrogates on disparities in African-American (AA) kidney transplantation (KTX) is needed. We conducted a 10-year retrospective longitudinal cohort study of electronically abstracted clinical data assessing the impact of surrogates on disparities in KTX. Clinical surrogates were assessed by posttransplant year (1, 2, 3 or 4) and defined as acute rejection (Banff ≥1A), mean SBP >140 mmHg, tacrolimus variability (CV) >40%, mean glucose >160 mg/dl and mean hemoglobin <10 g/dl. We utilized landmark methodology to minimize immortal time bias and logistic and survival regression to assess outcomes; 1610 KTX were assessed (54.2% AAs), with 1000, 468, 368 and 303 included in the year 1, 2, 3 and 4 complete case analyses, respectively. AAs had significantly higher odds of developing a clinical surrogate, which increased in posttransplant years three and four [OR year 1 1.99 (1.38-2.88), year 2 1.77 (1.20-2.62), year 3 2.35 (1.49-3.71), year 4 2.85 (1.72-4.70)]. Adjusting for the five clinical surrogates in survival models explained a significant portion of the higher risks of graft loss in AAs in post-transplant years three and four. Results suggest focusing efforts on improving late clinical surrogate management within AAs may help mitigate racial disparities in KTX.
需要更深入地了解临床替代指标对非裔美国人(AA)肾移植(KTX)差异的影响。我们进行了一项为期 10 年的回顾性纵向队列研究,通过电子提取的临床数据评估了替代指标对 KTX 差异的影响。移植后第 1、2、3 或 4 年评估临床替代指标,并定义为急性排斥反应(Banff ≥1A)、平均收缩压(SBP)>140mmHg、他克莫司变异系数(CV)>40%、平均血糖>160mg/dl 和平均血红蛋白<10g/dl。我们利用地标法最大限度地减少了不朽时间偏差,并利用逻辑和生存回归评估了结果;评估了 1610 例 KTX(54.2%为 AA),其中第 1、2、3 和 4 年完整病例分析分别纳入了 1000、468、368 和 303 例。AA 发生临床替代指标的几率明显更高,并且在移植后第 3 和第 4 年增加[OR 第 1 年 1.99(1.38-2.88),第 2 年 1.77(1.20-2.62),第 3 年 2.35(1.49-3.71),第 4 年 2.85(1.72-4.70)]。在生存模型中调整了 5 种临床替代指标,解释了 AA 在移植后第 3 和第 4 年移植失败风险较高的部分原因。结果表明,努力改善 AA 晚期临床替代指标的管理,可能有助于减少 KTX 中的种族差异。